FRACTYL HEALTH Business Summary

Fractyl Health Inc (GUTS) is a clinical-stage metabolic therapeutics company that generates revenue through the development and future commercialization of procedural and gene-based therapies targeting the root causes of type 2 diabetes (T2D) and obesity. The company’s primary business segments are centered on its Revita platform, an endoscopic procedural therapy designed to remodel the duodenal lining, and its Rejuva platform, a novel local gene therapy delivery system aimed at restoring insulin production. Currently in a pre-commercial phase, Fractyl is advancing its lead candidate, Revita, through the pivotal REMAIN-1 Phase 3 trial with topline results anticipated in the second half of 2026. Direct competitors include Electromed (ELMD), KORU Medical Systems (KRMD), and TriSalus Life Sciences (TLSI); Fractyl distinguishes itself as a pioneer in gut-targeted metabolic disease modification, shifting the treatment paradigm from chronic symptomatic management to durable, organ-level intervention. The company was co-founded by CEO Harith Rajagopalan, M.D., Ph.D., a former academic cardiologist and physician-scientist from Brigham and Women’s Hospital, and President/Chief Product Officer Jay D. Caplan, an industry veteran with over 20 years of medical device leadership at firms like Candela and InfraReDx. The executive team was recently strengthened by the appointment of Lara Smith Weber as Chief Financial Officer in January 2026, who previously served as CFO at Inari Medical, alongside Chief Scientific Officer Timothy Kieffer, Ph.D. Fractyl is backed by a high-pedigree investor base including Mithril Capital, General Catalyst, and Bessemer Venture Partners, with the board of directors chaired by Ajay Royan and featuring notable members such as former U.S. Senator William W. Bradley and Samuel Conaway of Boston Scientific.